Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease


      Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome that is closely associated with multiple factors such as obesity, hyperlipidemia, type 2 diabetes mellitus and hypertension, making it difficult to treat NAFLD effectively using any monotherapy available to date. In this study, we propose a novel combination therapy for NAFLD comprising ezetimibe (EZ), a cholesterol absorption inhibitor, and acarbose (AC), an α-glucosidase inhibitor.


      C57BL/6J mice were divided into five treatment groups as follows: basal diet (BD), high-fat diet (HFD) only, HFD with EZ (5 mg/kg/day), HFD with AC (100 mg/kg/day), and HFD with both EZ and AC for 24 weeks.


      Long-term combination therapy with EZ and AC significantly reduced steatosis, inflammation and fibrosis in the liver, compared with long-term monotherapy with either drug, in an HFD-induced NAFLD mouse model; the combination therapy also significantly increased the expression of microsomal triglyceride transfer protein (MTP) and peroxisome proliferators-activated receptor-α1 (PPAR-α1) in the liver, compared with either monotherapy, which may have led to the improvement in lipid metabolic disorder seen in this model.


      Combination therapy with EZ and AC for 24 weeks improved the histopathological findings in a mouse model of NAFLD.



      NAFLD (non-alcoholic fatty liver disease), EZ (ezetimibe), AC (acarbose), BD (basal diet), HFD (high-fat diet), NASH (non-alcoholic steatohepatitis), ALT (alanine aminotransferase), HPLC (high-performance liquid chromatography), Chol (cholesterol), TG (triglyceride), CM (chylomicron), VLDL (very low-density lipoprotein), LDL (low-density lipoprotein), HDL (high-density lipoprotein), HOMA-IR (homeostasis model assessment for insulin resistance), SREBP-1c (sterol regulatory element-binding protein-1c), SREBP-2 (sterol regulatory element-binding protein-2), PPAR-α1 (peroxisome proliferators-activated receptor-α1), MTP (microsomal triglyceride transfer protein), LDLR (low-density lipoprotein receptor), HMG CoA (3-hydroxy-3-methylguataryl CoA)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Abdelmalek M.F.
        • Diehl A.M.
        Nonalcoholic fatty liver disease as a complication of insulin resistance.
        Med Clin North Am. 2007; 91: 1125-1149
        • Gaede P.
        • Lund-Andersen H.
        • Parving H.H.
        • Pedersen O.
        Effect of a multifactorial intervention on mortality in type 2 diabetes.
        N Engl J Med. 2008; 7: 580-591
        • Koh K.K.
        • Quon M.J.
        Combination therapy for treatment or prevention of atherosclerosis.
        Hypertension. 2008; 52: e18
        • Athyros V.G.
        • Mikhailidis D.P.
        • Didangelos T.P.
        • Giouleme O.I.
        • Liberopoulos E.N.
        • Karagiannis A.
        • et al.
        Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
        Curr Med Res Opin. 2006; 22: 873-883
        • Altmann S.W.
        • Davis Jr., H.R.
        • Zhu L.J.
        • Yao X.
        • Hoos L.M.
        • Tetzloff G.
        • et al.
        Niemann–Pick C1 Like 1 protein is critical for intestinal cholesterol absorption.
        Science. 2004; 303: 1201-1204
        • Garcia-Calvo M.
        • Lisnock J.
        • Bull H.G.
        • Hawes B.E.
        • Burnett D.A.
        • Braun M.P.
        • et al.
        The target of ezetimibe is Niemann–Pick C1-Like 1 (NPC1L1).
        Proc Natl Acad Sci USA. 2005; 102: 8132-8137
        • Zheng S.
        • Hoos L.
        • Cook J.
        • Tetzloff G.
        • Davis Jr., H.
        • van Heek M.
        • et al.
        Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
        Eur J Pharmacol. 2008; 584: 118-124
        • Deushi M.
        • Nomura M.
        • Kawakami A.
        • Haraguchi M.
        • Ito M.
        • Okazaki M.
        • et al.
        Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
        FEBS Lett. 2007; 581: 5664-5670
        • Davies J.P.
        • Scott C.
        • Oishi K.
        • Liapis A.
        • Ioannou Y.A.
        Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia.
        J Biol Chem. 2005; 280: 12710-12720
        • Lieber C.S.
        • Leo M.A.
        • Mak K.M.
        • Xu Y.
        • Cao Q.
        • Ren C.
        • et al.
        Acarbose attenuates experimental non-alcoholic steatohepatitis.
        Biochem Biophys Res Commun. 2004; 315: 699-703
        • Usui S.
        • Hara Y.
        • Hosaki S.
        • Okazaki M.
        A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC.
        J Lipid Res. 2002; 43: 805-814
        • Wouters K.
        • van Gorp P.J.
        • Bieghs V.
        • Gijbels M.J.
        • Duimel H.
        • Lütjohann D.
        • et al.
        Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis.
        Hepatology. 2008; 48: 474-486
        • Lam K.S.
        • Tiu S.C.
        • Tsang M.W.
        • Ip T.P.
        • Tam S.C.
        Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
        Diabetes Care. 1998; 21: 1154-1158
        • Carrascosa J.M.
        • Molero J.C.
        • Fermı´n Y.
        • Martı´nez C.
        • Andrés A.
        • Satrústegui J.
        Effects of chronic treatment with acarbose on glucose and lipid metabolism in obese diabetic Wistar rats.
        Diabetes Obes Metab. 2001; 3: 240-248
        • Le Marchand-Brustel Y.
        • Rochet N.
        • Grémeaux T.
        • Marot I.
        • Van Obberghen E.
        Effect of an alpha-glycosidase inhibitor on experimentally-induced obesity in mice.
        Diabetologia. 1990; 33: 24-30
        • Lin M.C.
        • Gordon D.
        • Wetterau J.R.
        Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression.
        J Lipid Res. 1995; 36: 1073-1081
        • Lee S.S.
        • Pineau T.
        • Drago J.
        • Lee E.J.
        • Owens J.W.
        • Kroetz D.L.
        • et al.
        Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.
        Mol Cell Biol. 1995; 15: 3012-3022
        • Yeon J.E.
        • Choi K.M.
        • Baik S.H.
        • Kim K.O.
        • Lim H.J.
        • Park K.H.
        • et al.
        Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease.
        J Gastroenterol Hepatol. 2004; 19: 799-804
        • Horton J.D.
        Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis.
        Biochem Soc Trans. 2002; 30: 1091-1095
        • Sheng Z.
        • Otani H.
        • Brown M.S.
        • Goldstein J.L.
        Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver.
        Pro Natl Acad Sci USA. 1995; 92: 935-938
        • Shimano H.
        • Horton J.D.
        • Shimomura I.
        • Hammer R.E.
        • Brown M.S.
        • Goldstein J.L.
        Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells.
        J Clin Invest. 1997; 99: 846-854
        • Brown M.S.
        • Goldstein J.L.
        The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor.
        Cell. 1997; 89: 331-340
        • Repa J.J.
        • Turley S.D.
        • Quan G.
        • Dietschy J.M.
        Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption.
        J Lipid Res. 2005; 46: 779-789

      Linked Article